Physician profile
Mir Lim
NPI 1700462215
$2,290.24
in general payments reported to CMS, 2019-2025
14 companies · $683 in 2025
The $683 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $473 · 2024: $1,134 · 2025: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,460.52 |
| Education | $356.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $481.48 | 2024-2025 | |
| Abbvie INC. | $242.67 | 2024-2025 | |
| Syndax Pharmaceuticals, INC. | $173.45 | 2025 | Revuforj |
| E.R. Squibb & Sons, L.L.C. | $128.43 | 2024 | Reblozyl |
| Teva Pharmaceuticals USA, INC. | $128.09 | 2024 | Austedo Xr |
| Regeneron Healthcare Solutions, INC. | $117.77 | 2024-2025 | Libtayo, Lynozyfic |
| Emd Serono, INC. | $113.03 | 2024 | Mavenclad |
| Pfizer INC. | $105.17 | 2024 | |
| Amgen INC. | $94.19 | 2025 | Vectibix, Vectibix |
| Biogen, INC. | $82.33 | 2024 | Spinraza |
| Genentech USA, INC. | $68.00 | 2025 | |
| Janssen Biotech, INC. | $32.28 | 2025 | Darzalex, Talvey |
| Ipsen Biopharmaceuticals, INC | $27.62 | 2025 | Onivyde |
| Sobi, INC | $22.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mir Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.